Levodopa prodrug mesylate, compositions thereof, and uses...

Details Levodopa prodrug mesylate, compositions thereof, and uses... Levodopa prodrug mesylate, compositions thereof, and uses...

2011-06-28

2011-06-28

Keys, Rosalynd (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C514S533000, C514S534000, C514S537000, C560S012000, C560S014000, C560S039000, C560S040000

Reexamination Certificate

active

07968597

ABSTRACT:
(2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.

REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4038411 (1977-07-01), Saari
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4134991 (1979-01-01), Wermuth
patent: 4180509 (1979-12-01), Metcalf et al.
patent: 4311706 (1982-01-01), Bodor et al.
patent: 4663349 (1987-05-01), Repta
patent: 4771073 (1988-09-01), Repta
patent: 4826875 (1989-05-01), Chiesi
patent: 4873263 (1989-10-01), Repta
patent: 4914222 (1990-04-01), Budavari et al.
patent: 4966915 (1990-10-01), Tsuchiya et al.
patent: 4983400 (1991-01-01), Dempski et al.
patent: 5017607 (1991-05-01), Chiesi
patent: 5057321 (1991-10-01), Edgren et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5128145 (1992-07-01), Edgren et al.
patent: 5133974 (1992-07-01), Paradissis et al.
patent: 5190763 (1993-03-01), Edgren et al.
patent: 5283352 (1994-02-01), Backstrom et al.
patent: 5332576 (1994-07-01), Mantelle
patent: 5462933 (1995-10-01), Kramer et al.
patent: 5607969 (1997-03-01), Milman et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5827819 (1998-10-01), Yatvin et al.
patent: 5840756 (1998-11-01), Cohen et al.
patent: 6696600 (2004-02-01), Frenkel et al.
patent: 7101912 (2006-09-01), Xiang et al.
patent: 7323585 (2008-01-01), Xiang et al.
patent: 7342131 (2008-03-01), Xiang et al.
patent: 7534813 (2009-05-01), Xiang et al.
patent: 7563821 (2009-07-01), Xiang et al.
patent: 2002/0099041 (2002-07-01), Gallop et al.
patent: 2003/0152628 (2003-08-01), Licht et al.
patent: 2003/0158254 (2003-08-01), Zerangue et al.
patent: 2005/0209181 (2005-09-01), Akil et al.
patent: 2005/0282891 (2005-12-01), Xiang et al.
patent: 2006/0020028 (2006-01-01), Xiang et al.
patent: 2007/0225366 (2007-09-01), Xiange et al.
patent: 2008/0070984 (2008-03-01), Tran et al.
patent: 2008/0103200 (2008-05-01), Xiang et al.
patent: 2008/0132570 (2008-06-01), Xiang et al.
patent: 2008/0171789 (2008-07-01), Xiang et al.
patent: 2008/0214663 (2008-09-01), Xiang et al.
patent: 2009/0137834 (2009-05-01), Xiang et al.
patent: 2607198 (2006-11-01), None
patent: 0 309 827 (1989-04-01), None
patent: 1447599 (1976-08-01), None
patent: 1537951 (1979-01-01), None
patent: 58-024547 (1983-02-01), None
patent: WO 86/04579 (1986-08-01), None
patent: WO 88/01615 (1988-03-01), None
patent: WO 01/68065 (2001-09-01), None
patent: WO 02/28882 (2002-04-01), None
patent: WO 2005/121069 (2005-12-01), None
patent: WO 2005/121070 (2005-12-01), None
patent: WO 2007/067495 (2007-06-01), None
patent: WO 2007/087256 (2007-08-01), None
Claims for U.S. Appl. No. 12/726,978, filed Mar. 18, 2010.
Bai,Pharm. Res. 1995, 12(7), 1101-1104.
Betarbet et al.,Bioessays2002, 24(4), 308-18.
Bodor et al.,J. Med. Chem. 1977, 20(11):1435-1445.
Cho et al.,Biochem. Biophys. Res. Commun. 2006, 341, 6-12.
Coleman et al.,PolymersJul. 1990, 31, 1187-1203.
Cooper et al.,J. Pharm. Pharmacol. 1987, 39, 627-635.
Di Stefano et al.,Bioorganic & Medicinal Chem. Let. 11:1085-1088 (2001).
Durif et al.,Mov Disord1999, 14, 242-245.
During et al.,Ann. Neurol1989, 25, 351.
Emborg,J. Neuro. Meth. 2004, 139, 121-143.
Faulkner et al.,Ann. Pharmacother. 2003, 37(2), 282-6.
Fincher,J. Pharm. Sci. 1968, 57, 1825-1835.
Fix, et al.,Pharm. Res. 1989, 6, 501-5.
Fix, et al.,Pharm. Res. 1990, vol. 7, 7(4), 384-387.
Folstein et al.,J Psychiatr Res1975, 12, 189-198.
Gelb et al.,Arch NeurolJan. 1999, 56(1), 33-9.
Gibb et al.,J Neurol Neurosurg Psychiatry1988, 51, 745-752.
Giovanni et al.,J Neurol Neurosurg Psychiatry1999, 67, 624-629.
Hirsch et al.,J Neural Transm Suppl2003, 65, 89-100.
Hisaka et al.,Drug Metabolism and Disposition1990, 18(5), 621-625.
Hoes et al.,Drug Carrier Systems1989, 9, 57-100.
Howard et al.,J. Neurosurg1989, 71, 105-112.
Ishikura et al.,Int'l. J. Pharmaceutics116:51-63 (1995).
Juncos et al.,NeurologyJul. 1987, 37, 1242.
Langer,ScienceSep. 1990, 249, 1527-1533.
Langer and Peppas,J. Macromol. Sci. Rev. Macromol Chem1983, C23(1), 61-126.
Leong et al.,Adv. Drug Delivery Rev. 1987, 1, 199-233.
Leppert et al.,Pharmaceutical Res1988, 5(9), 587-591.
Levy et al.,Science1985, 228, 190-192.
Linhardt, R. J. (1989).Controlled release of drugs: polymers and aggregate systems(pp. 53-95). New York, N.Y.: VCH Publishers.
Lu,Int. J. Pharm. 1994, 112, 117-124.
Manson et al.,J Neurol Neurosurg Psychiatry2000, 68, 196-201.
Marrel et al.,Eur. J. Med. Chem. Chim. Ther. 1985, 5, 459-465.
Movement Disorder Society Task Force,Mov Disord2003, 18(7), 738-50.
Olson et al.,Am. J. Med. Jan. 1997, 102(1), 60-6.
O'Neil et al.,CNS Drug Rev. 2005, 11(1), 77-96.
Orth and Tabrizi,Mov Disord2003, 18(7), 729-37.
Sasahara,J. Pharm. SciMar. 1980, 69(3), 261-65.
Saudek et al.,N. Engl. J. Med. Aug. 1989, 321, 574.
Sefton,CRC Crit. Rev. Biomed. Eng. 1987, 14, 201-240.
Tolwani et al.,Lab Anim Sci1999, 49(4), 363-71.
Van Blercom et al.,Clin Neuropharmacol. Jun. 2004, 27(3), 124-8.
Verma et al.,Drug Dev. Ind. Pharm. 2000, 26, 695-708.
Wang et al.,J. Food and Drug Analysis 2002, 10(2):81-87.
Wang et al.,Bioorganic&Medicinal Chemistry Letters1995, 5(19), 2195-2198.
International Search Report and Written Opinion mailed Nov. 3, 2005, for International Application No. PCT/US2005/019492, filed Jun. 3, 2005.
International Search Report and Written Opinion mailed Nov. 3, 2005, for Application No. PCT/US2005/019493, filed Jun. 3, 2005.
International Search Report and Written Opinion mailed Jul. 23, 2007, for International Application No. PCT/US2006/046273, filed Dec. 4, 2006.
International Search Report and Written Opinion of the International Searching Authority mailed Apr. 15, 2008, for PCT Application No. PCT/US2007/026200 filed Dec. 20, 2007.
International Search Report and Written Opinion of the International Searching Authority mailed May 14, 2008, for PCT Application No. PCT/US2007/026271 filed Dec. 20, 2007.
Office Action mailed Nov. 24, 2006, for U.S. Appl. No. 11/145,159, filed Jun. 3, 2005.
Final Office Action mailed Jun. 15, 2007 for U.S. Appl. No. 11/145,159, filed Jun. 3, 2005.
Notice of Allowance mailed Oct. 10, 2007 for U.S. Appl. No. 11/145,159, filed Jun. 3, 2005.
Office Action mailed Jan. 19, 2007, for U.S. Appl. No. 11/145,280, filed Jun. 3, 2005.
Office Action mailed Apr. 17, 2007, for U.S. Appl. No. 11/145,280, filed Jun. 3, 2005.
Notice of Allowance, Notice of Allowability, and Examiner's Amendment mailed Sep. 11, 2007, for U.S. Appl. No. 11/145,280, filed Jun. 3, 2005.
Office Action mailed Mar. 21, 2008 for U.S. Appl. No. 11/634,354, filed Dec. 4, 2006.
Office Action mailed Sep. 16, 2008 for U.S. Appl. No. 11/634,354, filed Dec. 4, 2006.
Office Action mailed Oct. 24, 2008 for U.S. Appl. No. 12/001,618, filed Dec. 11, 2007.
Office Action mailed Jun. 3, 2008, for U.S. Appl. No. 12/008,473, filed Jan. 10, 2008.
Notice of Allowance mailed Oct. 15, 2008, for U.S. Appl. No. 12/008,473, filed Jan. 10, 2008.
Alpert and Friedhoff, Paradoxical reaction to L-dopa in schizophrenic patients,Am J Psychiatry1978, 135(11), 1329-1332.
Berge et al., Pharmaceutical Salts,J. Pharm. Sci.vol. 66, No. 1, Jan. 1977, 19 pages.
Boivin and Montplaisir, The effects of L-dopa on excessive daytime sleepiness in narcolepsy.Neurology1991, 41:1267-1269.
Bonelli and Wenning Pharmacological Management of Huntington's disease: an evidence-based review,Current Pharmaceutical Design2006, 12(21), 2701-2720.
Bruno and Bruno, Effects of L-dopa on pharmacological parkinsonism,Acta Psychiatr Scand1966, vol. 42, 264-271.
Buchanan et al., Double blind trial of L-dopa in chronic schizophrenia,.Aust N Z J Psychiatry1975, 9(4), 269-271.
Carb

Affiliated with

Also associated with

Rating

Levodopa prodrug mesylate, compositions thereof, and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Levodopa prodrug mesylate, compositions thereof, and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Levodopa prodrug mesylate, compositions thereof, and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2660370